Thiazolidinedione associated volume overload and pulmonary hypertension

Therapeutic Advances in Cardiovascular Disease
Jeffrey Michaelson

Abstract

Thiazolidinediones are currently indicated for the treatment of Type 2 Diabetes. This class of drugs has been associated with several adverse reactions associated with volume overload. This report describes a case of a 65 year old African-American female with a history of hypertension and obesity, and taking rosiglitazone (Avandia) for her Type 2 Diabetes whose evaluation for chest pain resulted in the incidental finding of pulmonary hypertension noted on echocardiogram. The subsequent evaluation, follow-up and treatment are discussed along with potential pitfalls and implications for clinical care.

References

Apr 20, 2001·The American Journal of the Medical Sciences·M A Alpert
Jun 26, 2001·Diabetes Care·P RaskinUNKNOWN Rosiglitazone Clinical Trials Study Group
Jul 20, 2002·Pharmacotherapy·Nancee V Niemeyer, Laurel M Janney
Oct 25, 2002·Diabetes Technology & Therapeutics·Fei WangCunegundo M Vergara
Jul 14, 2004·Chest·Charles W AtwoodUNKNOWN American College of Chest Physicians
May 23, 2007·The New England Journal of Medicine·Steven E Nissen, Kathy Wolski

❮ Previous
Next ❯

Citations

Aug 9, 2011·The Journal of Clinical Investigation·Tero-Pekka AlastaloMarlene Rabinovitch

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.